Evaluating High-Cost Cancer Drugs


Results of a survey demonstrate that there appears to be inconsistency among oncologists with regard to views on how long expensive cancer therapies should be given to extend life before the cost of such therapy is justified. Most respondents felt that adding 1 year to a patient’s life was worthwhile with a treatment that cost less than $100,000. However, the benefit that oncologists demand from new treatments in terms of length of survival does not appear to increase along with the price of that treatment.

Abstract: Health Affairs, April 2012.

Submit a Comment

Your email address will not be published. Required fields are marked *

18 + 20 =